Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

MLA

Chang, Vicky C., et al. “Serum Perfluorooctane Sulfonate and Perfluorooctanoate and Risk of Postmenopausal Breast Cancer According to Hormone Receptor Status: An Analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.” International Journal of Cancer, vol. 153, no. 4, Aug. 2023, pp. 775–82. EBSCOhost, https://doi.org/10.1002/ijc.34487.

APA

Chang, V. C., Rhee, J., Berndt, S. I., Moore, S. C., Freedman, N. D., Jones, R. R., Silverman, D. T., Gierach, G. L., Hofmann, J. N., & Purdue, M. P. (2023). Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. International Journal of Cancer, 153(4), 775–782. https://doi.org/10.1002/ijc.34487

Chicago

Chang, Vicky C, Jongeun Rhee, Sonja I Berndt, Steven C Moore, Neal D Freedman, Rena R Jones, Debra T Silverman, Gretchen L Gierach, Jonathan N Hofmann, and Mark P Purdue. 2023. “Serum Perfluorooctane Sulfonate and Perfluorooctanoate and Risk of Postmenopausal Breast Cancer According to Hormone Receptor Status: An Analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.” International Journal of Cancer 153 (4): 775–82. doi:10.1002/ijc.34487.